Organogenesis (NASDAQ:ORGO) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Organogenesis (NASDAQ:ORGO) from a sell rating to a strong sell rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the stock. BTIG Research lowered shares of Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. UBS Group set a $3.00 price target on shares of Organogenesis in a research note on Thursday, May 28th. Weiss Ratings lowered shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Truist Financial lowered their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a report on Friday. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Organogenesis currently has an average rating of “Reduce” and an average price target of $4.33.

Organogenesis Stock Down 22.8%

ORGO stock opened at $1.86 on Friday. The stock has a market cap of $239.34 million, a P/E ratio of -2.16 and a beta of 1.34. The company has a current ratio of 3.53, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. The stock’s fifty day simple moving average is $2.42 and its two-hundred day simple moving average is $2.76. Organogenesis has a 1-year low of $1.54 and a 1-year high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative net margin of 19.94% and a negative return on equity of 21.24%. The business had revenue of $43.76 million for the quarter, compared to analysts’ expectations of $54.27 million.

Institutional Investors Weigh In On Organogenesis

A number of institutional investors have recently made changes to their positions in the business. Quarry LP purchased a new position in Organogenesis in the 3rd quarter worth $25,000. Flagship Harbor Advisors LLC bought a new position in Organogenesis in the 4th quarter worth $34,000. Pallas Capital Advisors LLC purchased a new stake in Organogenesis in the second quarter worth $37,000. Federated Hermes Inc. increased its position in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after buying an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Organogenesis during the second quarter valued at approximately $45,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.